Non muscle invasive bladder cancer: How to improve surgical and medical management?

Poster Session 54

Sunday 18 March
15:45 - 17:15

Location: Green Area, Room 2 (Level 0)

Chairs: L-M. Krabbe, Münster (DE)
        R. Hurle, Bergamo (IT)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

728

Results of the phase-I open-label clinical trial SAKK 06/14 assessing safety of intravesical instillation of the recombinant BCG VPM1002BC in patients with non-muscle invasive bladder cancer and previous failure to conventional BCG therapy


1University Hospital Basel, Dept. of Urology, Basel, Switzerland, 2University Hospital Geneva, Dept. of Urology, Geneva, Switzerland, 3University of Basel, Alto Uro AG, Basel, Switzerland, 4Cantonal Hospital Chur, Dept. of Oncology, Chur, Switzerland, 5Vaccine Project Management GmBH, Hannover, Germany, 6Vaccine Project Management GmbH, Hannover, Germany, 7Serum Institute of India, Pune, India, 8University Hospital Basel, Dept. of Clinical Microbiology, Basel, Switzerland, 9Lausanne University Hospital, Division of Immunology and Allergy, Lausanne, Switzerland, 10Swiss Group for Clinical Cancer Research, Bern, Switzerland, 11University Hospital Basel, Dept. of Oncology, Basel, Switzerland

729

Improved outcome over time in TaG1G2 tumors


1Linköpings Universitet, Dept. of Experimental Medicine, Linköping, Sweden, 2Karolinska Institutet Danderyds Sjukhus, Dept. of Clinical Sciences, Stockholm, Sweden, 3Sahlgrenska Universitetssjukhuset, Dept. of Urology, Dept. of Clinical Sciences, Göteborg, Sweden, 4Karolinska Institutet, Dept. of Molecular Medicine and Surgery, Stockholm, Sweden, 5Umeå Universitet, Dept. of Surgical and Perioperative Science, Urology and Andrology, Umeå, Sweden, 6Karolinska Institutet, Dept. of Oncology Pathology, Stockholm, Sweden, 7Uppsala Universitet, Dept. of Surgical Sciences, Uppsala, Sweden, 8Lunds Universitet, Translational Medicine, Lund, Sweden

730

Performance evaluation of bladder EpiCheckTM for NMIBC monitoring: European multi-center pivotal study
Performance of bladder wash cytology during surveillance of non-muscle-invasive bladder cancer: Analysis in a contemporary patient cohort

By: Kranzbühler B. , Bieri U. , Poyet C. , Sulser T. , Hermanns T.
University Hospital Zürich, Dept. of Urology, Zürich, Switzerland

Oncofid-P-B (paclitaxel-hyaluronic acid) in the intravesical therapy of patients affected by primary or recurrent Ta G1-G2 papillary cancer of the bladder. A phase II marker lesion study

1A. Gemelli Foundation Hospital - Catholic University of Sacred Heart , Dept. of Urology, Rome, Italy, 2Azienda Ospedaliera Universitaria di Pisa, Dept. of Urology, Pisa, Italy, 3Ospedale consorziale Policlinico di Bari, Dept. of Urology, Bari, Italy, 4Ospedale Città della Salute e della Scienza di Torino, Dept. of Urology, Turin, Italy, 5Spedali Civili di Brescia, Dept. of Urology, Brescia, Italy, 6Praxisklinik urologie Rhein-Rurh, Dept. of Urology, Mülheim, Germany, 7Klinik und Poliklinik fur Urologie Kinderurologie und urologische Onkologie Universitatsklinikum , Dept. of Urology, Essen, Germany, 8Urologische Klinik und Poliklinik Universitatsmedizin der Johannes Gutenberg-Universitat, Dept. of Urology, Mainz, Germany, 9Hospital del Henares, Dept. of Urology, Madrid, Spain, 10Hospital La Laguna, Dept. of Urology, Santa Cruz de Tenerife, Spain, 11Instituto Valenciano de Oncologia, Dept. of Urology, Valencia, Spain, 12Hospital clinico San Carlos, Dept. of Urology, Madrid, Spain, 13Hospital Universitario Fundacion Alcorcon, Dept. of Urology, Madrid, Spain, 14Hospital del Mar, Dept. of Urology, Barcelona, Spain, 15Fidia Pharma Group, Dept. of Pharmaceuticals, Abano Terme, Italy

Early versus delayed radical cystectomy for clinical T1 bladder cancer

Keck School of Medicine, University of Southern California, USC Institute of Urology, Los Angeles, United States of America

Increasing incidence and more active therapy of patients with bladder cancer in Sweden: A population based registry study
Continuous saline bladder irrigation after transurethral resection is an alternative prophylactic strategy for the patients with non-muscle-invasive bladder cancer

By: Onishi T. 1, Shibahara T. 1, Sekito S. 1, Sasaki T. 2, Uchida K. 3
1Ise Red cross hospital, Dept. of Urology, Ise, Japan, 2Mie University, Dept. of Urology, Tsu, Japan, 3Mie University, Dept. of Pathology, Tsu, Japan

Results of CALIBER: A phase II randomised feasibility trial of chemoablation versus surgical management in low risk non-muscle invasive bladder cancer

1Royal Surrey County Hospital, Dept. of Urology, Guildford, United Kingdom, 2James Cook University Hospital, Dept. of Urology, Middlesbrough, United Kingdom, 3University Hospitals of Leicester NHS Trust, Clinical Sciences Unit, Leicester, United Kingdom, 4University College London Hospital, Dept. of Oncology, London, United Kingdom, 5Consumer Representative, Hampshire, United Kingdom, 6University of Sheffield, Academic Urology Unit, Sheffield, United Kingdom, 7Gloucestershire Hospitals NHS Foundation Trust, Dept. of Urology, Cheltenham, United Kingdom, 8University College London, UCL Cancer Institute, London, United Kingdom, 9St James's University Hospital, Leeds Institute of Cancer and Pathology, Leeds, United Kingdom, 10Royal Devon and Exeter NHS Foundation Trust, Exeter Surgical Health Services Research Unit, Exeter, United Kingdom, 11The Royal Wolverhampton Hospitals NHS Trust, Dept. of Urology, Wolverhampton, United Kingdom, 12Medway NHS Trust, Dept. of Urology, Gillingham, United Kingdom, 13Institute of Cancer Research, Clinical Trials and Statistics Unit, London, United Kingdom

Long-term follow-up in high risk non muscle invasive bladder cancer (NMIBC) “en-bloc” resection

Istituto Clinico Humanitas IRCCS, Dept. of Urology, Rozzano, Italy

ElectroMotive drug administration (EMDA) of mitomycin C as first line salvage therapy in high risk “BCG-failure” non muscle invasive bladder cancer: 3 years
followup outcomes

By: Di Gianfrancesco L., Racioppi M., Ragonese M., Palermo G., Lenci N., Sacco E., Bassi P.F.
Catholic University of the Sacred Heart, Dept. of Surgery, Rome, Italy

739

Is a biopsy from the tumor base after TURBT required?

E. Wolfson Medical Center, The Sackler Faculty of Medicine Tel-Aviv University, Dept. of Urologic Surgery, Holon, Israel

740

Day case primary transurethral resection of bladder tumour (TURBT) as standard protocol in a single UK centre. Should this be the new standard?

By: Austin T., Menzies-Wilson R., Robinson R., Forshaw C., Wilby D.
Queen Alexandra Hospital, Dept. of Urology, Portsmouth, United Kingdom

741

Discharge of low risk non muscle invasive bladder cancer after one year: Results of a national survey of the adoption of the NICE bladder cancer guidelines recommendations in the UK

By: Mostafid H., 1 Malde S., 2 Mir-Kohler A., 2 Bagnall P., 3 Taylor J., 4 Cresswell J., 5 Catto J 6
1Royal Surrey County Hospital, Dept. of Urology, Guildford, United Kingdom, 2Guy’s Hospital, Dept. of Urology, London, United Kingdom, 3Northumbria Healthcare NHS Foundation Trust, Dept. of Urology, Newcastle, United Kingdom, 4Salford Royal Foundation Trust, Dept. of Urology, Manchester, United Kingdom, 5James Cook University Hospital, Dept. of Urology, Middlesbrough, United Kingdom, 6Royal Hallamshire Hospital, Dept. of Urology, Sheffield, United Kingdom

742

Pathological substaging of pT1 urothelial bladder carcinoma is associated with tumor progression

By: Jeandin E., 1 Dupont A., 2 Tille J-C., 2 Hauser J., 1 Tran S-N., 1 Regusci S., 1 De Gorski A., 1 Iselin C., 1 Wirth G.J. 1
1Hôpitaux Universitaires de Genève, Dept. of Urology, Geneva, Switzerland, 2Hôpitaux Universitaires de Genève, Dept. of Pathology, Geneva, Switzerland